Phase 1/2a clinical trial to evaluate K-NK-ID101 in COVID-19 patients.

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Nov 2020 According to a Kiadis Pharma media release, it plans to initiate a phase 1/2a clinical trial evaluating use of K-NK cells to treat COVID-19 patients with government grant funding.
30 Sep 2020 According to a Kiadis Pharma media release,In support of this program, Kiadis is collaborating with five premier Dutch institutions to study different anti-viral mechanisms of Kiadis' K-NK cell therapy platform against SARS-CoV-2, the virus that caused the COVID-19 pandemic.
16 Sep 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com